Are novel oral oncolytics underdosed in obese patients?
Lishi LinEllen K O van der MeerNeeltje SteeghsJos H BeijnenAlwin D R HuitemaPublished in: Cancer chemotherapy and pharmacology (2023)
Higher body weight was only correlated with lower plasma trough levels for crizotinib, imatinib, and trametinib. Therefore, patients with a high body weight may require dose escalation to obtain adequate target levels when treated with these oral oncolytics.